¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31
±³À°ÀÏÀÚ : 2022-03-31
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) 
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
´ã´çÀÚ : Çѹ®¼÷
¿¬¶ôó : 02-566-6031  
À̸ÞÀÏ : icksh@icksh.org      
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú      
Âü¼®¿¹»óÀοø : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 55ºÐ  
¼¼ºÎ¼ö°­·á : 150,000¿ø      
ºñ°í 2¿ù 28ÀϱîÁö 100,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-31 Room 1 09:00~09:20 Next generation CAR-T cell therapy against hematological malignancies  ÃÖ°æÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 09:20~09:40 Effective conditioning regimen in adoptive T cell therapy of cancer  ÇÑÁØ¿µ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 03-31 Room 1 09:40~10:05 Tissue resident memory T cells in multiple myeloma  ÃÖÀ±¼÷(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 10:05~10:30 T-cell-based immunotherapeutic strategies against EBV(Epstein-Barr virus)-positive malignancies using the novel TCR(T-Cell Receptor) specific for LMP1(latent membrane protein) antigen  ±èűÔ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 1 10:30~11:15 Immune landscape of hematological malignancies and functional screening tools  Satu Mustjoki(University of Helsinki Finland) 
±³À°½Ã°£ 03-31 Room 1 11:30~12:10 What is the role of C5 inhibitors in PNH(Paroxysmal nocturnal hemoglobinuria)?  ±èÁø¼®(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 12:40~13:40 Potential prognostic significance of promoter methylation status of DNA repair genes at diagnosis in Acute myeloid leukemia: analysis of TCGA(Acute Myeloid Leukemia)-LAML(acute myeloid leukemia) cohort and patients in a single institution  ¹Ú¼³Èñ(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 13:55~14:25 Recent advances in molecular diagnosis, prognosis and monitoring of MPNs(myeloproliferative neoplasm)  ±è¸í½Å(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 03-31 Room 2 14:25~14:55 Molecular mechanisms underlying the development of MPN(myeloproliferative neoplasm) by mutant calreticulin and the therapeutic potential of an antibody targeting mutant calreticulin  Norio Komatsu(Juntendo University Japan) 
±³À°½Ã°£ 03-31 Room 2 14:55~15:25 Modeling improved targeting of JAK2V617F in MPNs(myeloproliferative neoplasm)  Andrew J. Dunbar(Memorial Sloan Kettering Cancer Center USA) 
±³À°½Ã°£ 03-31 Room 3 15:40~16:10 Immune landscapes and chemotherapy resistance in AML(cute myeloid leukemia)  Sergio Rutella(Nottingham Trent University UK) 
±³À°½Ã°£ 03-31 Room 3 16:10~16:40 Towards next-generation T cell engineering for cancer  ±èÂùÇõ(KAIST) 
±³À°½Ã°£ 03-31 Room 3 16:40~17:10 Endogenous retroviruses as a source of tumor antigens in solid tumors and acute myeloid leukemia  Stéphane Depil(Université Claude Bernard Lyon France) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-3¿ù 31ÀÏ(1ÀÏÂ÷) : 2022-03-31""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ) 2022 ´ëÇÑÇ÷¾×ÇÐȸ ±¹Á¦Çмú´ëȸ(ICKSH 2022)-4¿ù 1ÀÏ(2ÀÏÂ÷) : 2022-04-01
´ÙÀ½±Û (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2022-03-30
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
390 °æ±â ¾ÆÁÖ´ëÇб³º´¿ø 2018³â ¾ÆÁÖ´ëÇб³ ¸¶ÃëÅëÁõÀÇÇаú Ãß°è Çмú´ëȸ : 2018-09-01 0 1,222 2018-08-15
389 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7Â÷ International Congress on Lipid Metabolism & Atherosclerosis (ICoLA 2018) : 2018-09-01 0 556 2018-08-15
388 °æ³² â¿ø°æ»ó´ëÇб³º´¿ø 2018³â Áߺΰ泲 ¿¬¼ö±³À° : 2018-09-01 0 904 2018-08-15
387 °­¿ø Á¦19ȸ ´ëÇÑ Ã´Ãß¿Ü°úÇÐȸ ôÃßÅëÁõ¿¬±¸È¸ ½ÉÆ÷Áö¿ò : 2018-09-01 0 834 2018-08-15
386 ºÎ»ê Á¦15ȸºÎ¿ï°æÇǺΰúÀÇ»çȸÇмú´ëȸ : 2018-09-01 0 1,045 2018-08-15
385 ¼­¿ï 2018 ¼­¿ï¾Æ»êº´¿ø À̺ñÀÎÈÄ°ú Ãß°è ÀÓ»ó ¿öÅ©¼¥ : 2018-09-01 0 760 2018-08-15
384 ´ëÀü ´ëÇÑÁ¤Çü¿Ü°úÇÐȸ Á¤Çü¿Ü°úÁúȯ, ¼Õ»ó, Ä¡·á : 2018-09-01 0 1,445 2018-08-15
383 ¼­¿ï Preterm Birth International Collaborative Australasian(´ëÇÑ»êºÎÀΰúÇÐȸ&¼¼°èÁ¶»êÇÐȸ °øµ¿ÁÖ°ü) : 2018-08-31 0 1,099 2018-08-15
382 ¼­¿ï Çѱ¹Á÷¹«½ºÆ®·¹½ºÇÐȸ 2018³â ÇÏ°èÇмú´ëȸ : 2018-08-31 0 556 2018-08-15
381 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7Â÷ International Congress on Lipid Metabolism & Atherosclerosis (ICoLA 2018) : 2018-08-31 0 583 2018-08-15
380 ºÎ»ê ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ºÎ»êÁöºÎÇÐȸ 8¿ù ¿ù·ÊÁý´ãȸ : 2018-08-30 0 1,234 2018-08-15
379 °­¿ø ¿øÁÖ ¼¼ºê¶õ½º ±âµ¶º´¿ø ±âÃʾȰúÁúȯ / CÇü °£¿° : 2018-08-29 0 2,219 2018-08-15
378 ¼­¿ï ´ëÇѼҾư¨¿°ÇÐȸ Á¦154Â÷ ¿ù·Ê¿¬¼ö°­ÁÂ(°¨¿°°ü¸® ¿¬¼ö±³À°) : 2018-08-28 0 602 2018-08-15
377 ¼­¿ï Á¦12ȸ ÁöµµÀü¹®ÀÇ Àü¹®ÇÐȸ(°¡Á¤ÀÇÇÐȸ) ±³À° : 2018-08-25 0 864 2018-08-15
376 ¼­¿ï Á¦13Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ ¼­¿ï°æÀÎ(°­¿ø-Á¦ÁÖ)Áöȸ : 2018-08-25 0 706 2018-08-15
1361 | 1362 | 1363 | 1364 | 1365 | 1366 | 1367 | 1368 | 1369 | 1370
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷